Array Biopharma announces 15.3 months median overall OS from phase III BEACON CRC trial in colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Array BioPharma Inc. announced updated safety and efficacy results, including mature overall survival, from the safety lead-in of the phase III BEACON CRC trial evaluating the triplet combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor and Erbitux (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login